Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 7/20 | 0.39 |
| ▸ | BRD4 | O60885 | 7/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060402 | 0.82 | BRD4 (0.37) | BRD4 | |
| SCHEMBL3059559 | 0.76 | GRIN1 (0.37) | BRD4 | |
| SCHEMBL3049980 | 0.73 | CYP3A4 (0.35) | RPS6KA5BRD4 | |
| SCHEMBL3067519 | 0.73 | GRM2 (0.39) | RPS6KA5BRD4PDE2A | |
| SCHEMBL3059480 | 0.73 | TP53 (0.43) | BRD4 | |
| SCHEMBL3057738 | 0.72 | GRM2 (0.39) | RPS6KA5BRD4DYRK1ARPS6KB1CDK2 | |
| SCHEMBL3404622 | 0.72 | TSHR (0.38) | RPS6KA5BRD4 | |
| SCHEMBL3050704 | 0.72 | RPS6KA5 (0.41) | RPS6KA5BRD4DYRK1ARPS6KB1CDK2 | |
| SCHEMBL3064975 | 0.71 | BRD4 (0.39) | RPS6KA5BRD4 | |
| SCHEMBL3061412 | 0.71 | RPS6KA5 (0.48) | RPS6KA5BRD4DYRK1ARPS6KB1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | RPS6KA5 2860/4885BRD4 138/4885DYRK1A 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.